RecruitingNCT05306600

Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Sponsor

Hospital Moinhos de Vento

Enrollment

882 participants

Start Date

Nov 9, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Prostate Cancer

Summary

This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program, called Genomas Brasil, as well as to collect data on the population's ancestry.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (Onco-Genomas Brasil) maps the genetic features of breast cancer and prostate cancer in patients receiving treatment through Brazil's public health system, aiming to understand cancer biology in the Brazilian population and improve access to personalized treatments. **You may be eligible if...** - You are a woman aged 18 or older, a Brazilian citizen, with confirmed HER2-positive or triple-negative breast cancer - Your breast cancer is at clinical stage I–III (stage II–III for HER2-positive, stage I–III for triple-negative) - You are eligible for standard neoadjuvant chemotherapy (chemotherapy before surgery) - You are being treated at Hospital Moinhos de Vento **You may NOT be eligible if...** - You have a different breast cancer type (e.g., hormone receptor-positive, HER2-negative) - You are not a Brazilian citizen - You are not eligible for standard neoadjuvant treatment protocols Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTwhole exome and whole genome sequencing analysis

Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer

Locations(25)

Fundação Centro de Controle de Oncologia do Estado do Amazonas

Manaus, Amazonas, Brazil

Hospital Universitário Getúlio Vargas

Manaus, Amazonas, Brazil

Hospital Santa Rita de Cássia - AFECC

Vitória, Espírito Santo, Brazil

Hospital Calixto Midlej Filho/ Santa Casa de Itabuna

Itabuna, Estado de Bahia, Brazil

Serviço de Assistência Médica e Urgência S.A. SAMUR

Vitória da Conquista, Estado de Bahia, Brazil

Hospital Universitário de Brasília

Brasília, Federal District, Brazil

Hospital do Câncer do Maranhão

São Luís, Maranhão, Brazil

Hospital da Santa Casa de Misericórdia

Belo Horizonte, Minas Gerais, Brazil

Hospital das Clínicas

Belo Horizonte, Minas Gerais, Brazil

Hospital do Câncer/União Oeste Paranaense de Estudo e Combate ao Câncer

Cascavel, Paraná, Brazil

Hospital do Câncer de Londrina

Londrina, Paraná, Brazil

Hospital Ophir Loyola

Belém, Pará, Brazil

Hospital Universitário João de Barros Barreto

Belém, Pará, Brazil

Liga Norte Riograndense Contra o Câncer

Natal, Rio Grande do Norte, Brazil

Hospital Escola da Universidade Federal de Pelotas

Pelotas, Rio Grande do Sul, Brazil

Hospital do Amor

Barretos, São Paulo, Brazil

Hospital Universitário Maria Aparecida Pedrossian

Campo Grande, Brazil

Hospital Araújo Jorge

Goiânia, Brazil

Hospital de Clínicas de Porto Alegre

Porto Alegre, Brazil

Hospital São Lucas da PUCRS

Porto Alegre, Brazil

Grupo Hospitalar Conceição

Porto Alegre, Brazil

Hospital Fêmina

Porto Alegre, Brazil

Instituto Nacional do Câncer (INCA)

Rio de Janeiro, Brazil

Hospital São Camilo

São Paulo, Brazil

Hospital Universitário Cassiano Antônio de Moraes

Vitória, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05306600

Related Trials

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

NCT070504333 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT072146624 locations

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693226 locations

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT058799261238 locations

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965384 locations